Phaseline

Companies › Novartis

Novartis: clinical trials, targets and expected readouts

108 active drug programs in 577 registered trials: 258 Phase 2, 165 Phase 1, 119 Phase 3, 35 Phase 4; Oncology, Neurology, Immunology, Cardiovascular; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Dabrafenib
Serine/threonine-protein kinase B-raf inhibitor
BRAFPhase 4Diffuse Astrocytoma; Melanoma; Differentiated Thyroid Cancer (DTC); Advanced Thyroid Cancer Patients Who Received Target Therapy …Nov 2026
Trametinib
Dual specificity mitogen-activated protein kinase kinase 2 inhibitor; Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor
MAP2K2, MAP2K1Phase 4Diffuse Astrocytoma; Melanoma; Differentiated Thyroid Cancer (DTC); EGFR-mutant Non-small Cell Lung Cancer …Nov 2026
Inclisiran sodium
PCSK9 mRNA rnai inhibitor
PCSK9Phase 4Hypercholesterolaemia; Plaque, Atherosclerotic; Coronary Heart Disease; Coronary Artery Disease …Nov 2026
Lutetium Lu-177 Vipivotide Tetraxetan (AAA617)
Glutamate carboxypeptidase II binding agent
FOLH1Phase 4Prostate Cancer; Prostatic Neoplasms; Oligometastatic Prostate Cancer (OMPC); Metastatic Castration Resistant Prostate Cancer (mCRPC) …Dec 2026
Ribociclib (LEE011)
Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor
CDK4, CDK6Phase 4Metastatic Breast Cancer; Early Breast Cancer; Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies; Breast Cancer …Dec 2026
everolimus
FK506-binding protein 1A inhibitor
FKBP1APhase 4Renal Angiomyolipoma; Tuberous Sclerosis Complex; Advanced Breast Cancer; Renal Cell Carcinoma …Dec 2026
Ceritinib (LDK378)
ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor; NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor
ALK, EML4, NPM1Phase 4ALK Positive Malignancies; ALK-positive NSCLC; Neuroblastoma; ALK Positive …Apr 2027
Ofatumumab
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 4Multiple Sclerosis; Relapsing-Remitting Multiple Sclerosis; Relapsing Multiple Sclerosis; Relapsing Multiple Sclerosis (RMS) …Apr 2027
Asciminib
Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 4Chronic Myelogenous Leukemia; Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive; Philadelphia Chromosome-Positive Chronic Myeloid Leukemia; Chronic Myelogenous Leukemia - Chronic Phase …Sep 2027
Fingolimod
Sphingosine 1-phosphate receptor agonist; Sphingosine 1-phosphate receptor binding agent
S1PR5, S1PR2, S1PR4, S1PR3, S1PR1Phase 4Multiple Sclerosis; Diabetes Mellitus, Type 2; Non Small Cell Lung CancerSep 2027
Secukinumab
Interleukin 17A inhibitor
IL17APhase 4Non-radiographic Axial Spondyloarthritis; Hidradenitis Suppurativa (HS); Autoimmunity, Inflammation; Polymyalgia Rheumatica …Feb 2028
ETNA-ProgMS
Software as a Medical Device (SaMD) for tracking eye movements as biomarkers of neurologic
–Phase 4Relapsing Remitting Multiple Sclerosis (RRMS)Nov 2028
Crizanlizumab (SEG101)
P-selectin blocker
SELPPhase 4Sickle Cell Disease; Sickle Cell Disease (SCD); Advanced GlioblastomaJul 2029
panobinostat
Histone deacetylase inhibitor
HDAC (class I/II)Phase 4Primary Myelofibrosis; Sickle Cell DiseaseApr 2032
Onasemnogene Abeparvovec-brve (ITVISMA®)
Adeno-associated virus serotype 9 (AAV9) delivering SMN1 gene
SMN1Phase 4Spinal Muscular AtrophyMay 2032
Pelabresib
Bromodomain and extra-terminal motif (BET) inhibitor
BRD2, BRD4, BRDT, BRD3Phase 3Hematologic Malignancy; Myelofibrosis; Primary Myelofibrosis (PMF); Healthy Participants …Nov 2026
Iptacopan
Complement factor B inhibitor
CFBPhase 3C3G; Generalized Myasthenia Gravis; Paroxysmal Nocturnal Hemoglobinuria; Atypical Hemolytic Uremic Syndrome …Dec 2026
JDQ443
KRAS G12C inhibitor
KRASPhase 3Non-Small Cell Lung Cancer; Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation; KRAS G12C Mutant Solid Tumors; NSCLCJan 2027
Alpelisib (BYL719)
PI3-kinase p110-alpha subunit inhibitor
PIK3CAPhase 3Breast Cancer; Advanced HER2+Breast Cancer; Breast Neoplasms; Advanced Breast Cancer …Jan 2027
remibrutinib (LOU064)
Bruton's tyrosine kinase (BTK) inhibitor
BTKPhase 3Chronic Spontaneous Urticaria (CSU); Hidradenitis Suppurativa; Chronic Spontaneous Urticaria; Generalized Myasthenia Gravis …Feb 2027
Ianalumab (VAY736)
Tumor necrosis factor receptor superfamily member 13C binding agent
TNFRSF13CPhase 3Systemic Lupus Erythematosus; Sjogren Syndrome; Lupus Nephritis; Primary Immune Thrombocytopenia …Mar 2027
Tisagenlecleucel (CTL019)
B-lymphocyte antigen CD19 binding agent
CD19Phase 3B-cell Acute Lymphoblastic Leukemia; Follicular Lymphoma (FL); Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program; B-Cell Acute Lymphoblastic Leukemia …Mar 2027
Zigakibart (BION-1301, FUB523)–Phase 3IgA Nephropathy; Kidney Diseases; Immunoglobulin A Nephropathy (IgAN)Aug 2027
NIO752
antisense oligonucleotide
–Phase 3Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS); Alzheimer DiseaseSep 2027
Indacaterol (QVM149)
Beta-2 adrenergic receptor agonist
ADRB2Phase 3AsthmaFeb 2028
Pelacarsen (TQJ230)
LPA mRNA antisense inhibitor
LPAPhase 3Atherosclerotic Cardiovascular Disease (ASCVD); Hyperlipoproteinemia (a); Cardiovascular Disease and Lipoprotein(a); Atherosclerotic Cardiovascular Disease …Feb 2028
Atrasentan
Endothelin receptor ET-A antagonist
EDNRAPhase 3IgA Nephropathy; Berger DiseaseApr 2028
Omalizumab
Ig epsilon chain C region inhibitor
IGHEPhase 3Chronic Spontaneous Urticaria; Food Allergy; Asthma; Chronic Sinusitis …May 2028
AAA817–Phase 3Prostate CancerJun 2028
Enzalutamide
Androgen Receptor antagonist
ARPhase 3Prostate Cancer; Castration-Resistant Prostatic Cancer; Prostatic Neoplasms; Castration-Resistant Prostate Carcinoma …Sep 2028
[177Lu]Lu-DOTA-TATE
SSTR2-targeted radioligand therapy with lutetium-177
SSTR2Phase 3Somatostatin Receptor Positive (SSTR+); Metastatic Neuroendocrine Prostate CancerDec 2028
Votoplam
HTT-lowering antisense oligonucleotide
HTTPhase 3Huntington DiseaseJul 2029
Siponimod
Sphingosine 1-phosphate receptor Edg-1 agonist
S1PR1Phase 3Multiple Sclerosis (MS); Alzheimer DiseaseFeb 2031
onasemnogene abeparvovec
Survival motor neuron protein exogenous gene
SMN2, SMN1Phase 3Spinal Muscular Atrophy (SMA)Apr 2031
Onasemnogene Abeparvovec
Survival motor neuron protein exogenous gene
SMN2, SMN1Phase 3Spinal Muscular Atrophy Type IDec 2035
Eltrombopag
Thrombopoietin receptor agonist
MPLPhase 2Myelodysplastic SyndromesDec 2026
Fulvestrant
Estrogen receptor alpha antagonist; Estrogen receptor degrader
ESR1Phase 2Advanced Breast Cancer; Breast CancerDec 2026
[177Lu]Lu-PSMA-617
PSMA-targeted radioligand therapy with lutetium-177
FOLH1, GRPRPhase 2Metastatic Castration-Resistant Prostate Cancer (mCRPC); Metastatic Neuroendocrine Prostate Cancer; Metastatic Castration-resistant Prostate CancerJan 2027
JSB462 (luxdegalutamide)
GLP-1 receptor agonist
GLP1RPhase 2Prostatic Cancer, Castration-Resistant; Metastatic Hormone-sensitive Prostate Cancer; Metastatic Prostate Cancer (mCRPC); Progressive Metastatic Castrate Resistant Prostate CancerJan 2027
LTT462
RAF inhibitor
–Phase 2MelanomaFeb 2027
Naporafenib (LXH254)
B-raf/RAF proto-oncogene serine/threonine-protein kinase inhibitor
RAF1, BRAFPhase 2Melanoma; EGFR-mutant Non-small Cell Lung CancerFeb 2027
Cipargamin (KAE609)
P-type ATPase inhibitor
PFATP4Phase 2Uncomplicated Plasmodium Falciparum MalariaFeb 2027
KLU156
Fixed-dose combination of KAF156 + lumefantrine
–Phase 2Uncomplicated Plasmodium Falciparum MalariaFeb 2027
PKN605–Phase 2Atrial Fibrillation; Participants With Moderate and Severe Renal Impairment and Healthy ParticipantsMar 2027
EDI048–Phase 2CryptosporidiosisMar 2027
Arumakimig (MAS825)–Phase 2Hidradenitis Suppurativa; Still´s Disease; VEXAS Syndrome; NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 MutationsApr 2027
DII235
Lipoprotein(a) lowering agent
–Phase 2Lipoprotein DisorderApr 2027
QCZ484
KRAS G12C inhibitor
–Phase 2Hypercholesterolaemia; Hypertension; Hypertension (HTN)Apr 2027
GIA632
GPCR agonist
–Phase 2Atopic Dermatitis; Non-segmental Vitiligo; Cutaneous Lichen PlanusMay 2027
Spartalizumab (PDR001)
Programmed cell death protein 1 antagonist
PDCD1Phase 2Myelodysplastic Syndromes; Carcinoma, Non-Small-Cell Lung; Advanced Solid Tumors; Squamous Cell Anal Carcinoma …Jun 2027
Rapcabtagene autoleucel–Phase 2Lupus Erythematosus, Systemic; Scleroderma, Diffuse; Idiopathic Inflammatory Myopathies; ANCA Associated Vasculitis (AAV) …Jun 2027
Capmatinib
Hepatocyte growth factor receptor inhibitor
METPhase 2Advanced Solid Tumors Which Are cMET-dependent; EGFR-mutant Non-small Cell Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma; Solid TumourJul 2027
Nazartinib
Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor inhibitor
EGFRPhase 2Advanced Solid Tumors Which Are cMET-dependent; EGFR-mutant Non-small Cell Lung CancerJul 2027
EYU688–Phase 2DengueJul 2027
LXE408–Phase 2Chagas DiseaseJul 2027
GXV813–Phase 2SchizophreniaJul 2027
Glycopyrronium bromide
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist
CHRM3, CHRM1Phase 2Asthma; Post-Dural Puncture HeadacheJul 2027
YMI024–Phase 2Coronary Artery DiseaseAug 2027
Sabatolimab (MBG453)
Hepatitis A virus cellular receptor 2 inhibitor
HAVCR2Phase 2Myelodysplastic SyndromesFeb 2028
VHB937–Phase 2Amyotrophic Lateral Sclerosis (ALS); Alzheimer's DiseaseJul 2028
GHZ339–Phase 2Atopic DermatitisNov 2028
DDY391
Unclear - mechanism not stated in registry text
–Phase 2Moderate to Severe Psoriatic Arthritis; Sjögren's DiseaseDec 2028
Midostaurin
Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor
FLT3, KIT, PDGFRB, PDGFRA, PRKD3Phase 2FLT3-mutated Acute Myeloid Leukemia; AML/MDS; Acute Myeloid LeukemiaMay 2029
FWY003–Phase 2Geographic Atrophy Secondary to Age-related Macular DegenerationAug 2029
INE963–Phase 2Uncomplicated Plasmodium Falciparum Malaria–
Iscalimab (CFZ533)
Tumor necrosis factor receptor superfamily member 5 inhibitor
CD40Phase 2Hidradenitis Suppurativa–
LYS006
Bruton's tyrosine kinase (BTK) inhibitor
–Phase 2Hidradenitis Suppurativa–
HJB647–Phase 1Heart Failure With Reduced Ejection Fraction; Elevated Blood PressureDec 2026
[177Lu]Lu-NeoB
GRPR-targeted radioligand therapy
GRPRPhase 1Breast Cancer; Newly Diagnosed and Recurrent GlioblastomaDec 2026
PIT565
CD19-directed T cell engager
–Phase 1B-cell Non-Hodgkin Lymphoma (B-NHL); Systemic Lupus Erythematosus, SLE; Rheumatoid ArthritisJan 2027
IAG933
YAP/TAZ pathway inhibitor
–Phase 1MesotheliomaJan 2027
Batoprotafib (TNO155)
Protein-tyrosine phosphatase 2C inhibitor
PTPN11Phase 1KRAS G12C Mutant Solid TumorsJan 2027
DFV890–Phase 1Myeloid DiseasesFeb 2027
Lutetium Oxodotreotide
Somatostatin receptor binding agent
SSTR5, SSTR2, SSTR4, SSTR1, SSTR3Phase 1Glioblastoma; Extensive Stage Small Cell Lung CancerMay 2027
ARV-766
Androgen receptor antagonist
ARPhase 1Prostate Cancer MetastaticMay 2027
DKY709
Novel immunomodulatory agent
–Phase 1Carcinoma, Non-Small-Cell LungJun 2027
[68Ga]Ga-NeoB
Gallium-68 radiopharmaceutical PET imaging agent targeting neurotensin receptors
–Phase 1Newly Diagnosed and Recurrent GlioblastomaAug 2027
HRO761–Phase 1MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal CancersAug 2027
DYP688
GNAQ/GNA11 inhibitor
GNAQ, GNA11Phase 1Metastatic Uveal MelanomaOct 2027
KFA115
Immunomodulatory agent
–Phase 1Carcinoma, Non-Small-Cell LungOct 2027
177Lu-FAP-2286
FAP-targeted peptide radioligand (177Lu-labeled)
FAPPhase 1Solid TumorDec 2027
68Ga-DFC413
Radioimaging agent
–Phase 1Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Jan 2028
68Ga-NNS309
Radioimaging agent
–Phase 1Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Jan 2028
OJR520–Phase 1Chronic Kidney DiseaseJan 2028
DCY636
unclear mechanism
–Phase 1Dermatitis, AtopicJan 2028
EDK060–Phase 1Charcot-Marie-Tooth Disease, Type 1AFeb 2028
ITU512
Fetal hemoglobin (HbF) inducer
–Phase 1Sickle Cell DiseaseMay 2028
[68Ga]Ga-DWJ155
Radioligand imaging agent
–Phase 1Advanced Gastroesophageal Adenocarcinoma; Breast Neoplasms; Breast CancerJun 2028
AMO959
DNA Damage Response inhibitor
–Phase 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based ChemotherapyJul 2028
ECI830–Phase 1Advanced HR+/HER2- Breast CancerSep 2028
LTP001–Phase 1Healthy Volunteers, Pulmonary Arterial HypertensionNov 2028
[177Lu]Lu-DFC413
Therapeutic radiopharmaceutical (lutetium-177-labeled)
–Phase 1Pancreatic Ductal AdenocarcinomaMay 2029
[68Ga]Ga-NNS309
Diagnostic radiopharmaceutical (gallium-68-labeled)
–Phase 1Pancreatic Ductal AdenocarcinomaMay 2029
Opnurasib
KRAS inhibitor
KRASPhase 1Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung CancerJun 2029
YTB323
CAR-T cell therapy targeting muscle-specific kinase (MuSK)
–Phase 1Generalized Myasthenia GravisOct 2029
Tulmimetostat (DZR123, CPI-0209)
Dual EZH1/EZH2 inhibitor
EZH1, EZH2Phase 1Progressive Metastatic Castrate Resistant Prostate Cancer; Advanced Solid Tumor; Metastatic Hormone-Sensitive Prostate Cancer (mHSPC); Mycosis FungoidesNov 2029
INR731–Phase 1Metastatic Castration-resistant Prostate Cancer (mCRPC)Jun 2030
IDH305
Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
IDH1Phase 1Advanced Malignancies That Harbor IDHR132 MutationsOct 2030
[177Lu]Lu-NNS309
Radioligand therapy (radiotherapeutic agent)
–Phase 1Pancreatic Ductal AdenocarcinomaJan 2031
DJI136
DLL3-targeted CAR-T therapy
DLL3Phase 1Extensive-stage Small Cell Lung Cancer (ES-SCLC)Mar 2031
[225Ac]Ac-PSMA-R2
Alpha-emitting radiopharmaceutical targeting PSMA; 225Ac-labeled PSMA ligand
FOLH1Phase 1Prostate CancerMar 2031
GVV858–Phase 1Advanced HR+/HER2- Breast CancerMay 2031
DFT383
Autologous hematopoietic stem cell (HSC) gene therapy
–Phase 1Nephropathic CystinosisMay 2031
[111In]In-ETN029
Indium-111 labeled imaging agent targeting DLL3
DLL3Phase 1Small Cell Lung CarcinomaAug 2031
[225Ac]Ac-ETN029
Alpha-emitting radioligand targeting DLL3
DLL3Phase 1Small Cell Lung CarcinomaAug 2031
[177Lu]Lu-DWJ155
Radioligand therapy (Lu-177 labeled)
–Phase 1Breast CancerMay 2032
IEV407–Phase 1Advanced HR+/HER2- Breast CancerJun 2032
OTQ923
Genome-edited autologous hematopoietic stem and progenitor cells (HSPC)
–Phase 1Sickle Cell DiseaseJan 2039

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03814746Crizanlizumab (SEG101)Phase 3Sickle Cell Disease (SCD)HematologyAug 2022
NCT03753243EnzalutamidePhase 2Prostate CancerOncologySep 2022
NCT04689828Lutetium Lu-177 Vipivotide Tetraxetan (AAA617)Phase 3Prostatic NeoplasmsOncologyOct 2022
NCT04430192Lutetium Lu-177 Vipivotide Tetraxetan (AAA617)Phase 1Prostatic NeoplasmsOncologyDec 2022
NCT02881242TrametinibPhase 2Hormone-Resistant Prostate CancerOncologyJan 2024
NCT04573920AtrasentanPhase 2IgA NephropathyGenitourinaryJul 2024
NCT01990196TrametinibPhase 2Prostate CancerOncologySep 2024
NCT01990196EnzalutamidePhase 2Prostate CancerOncologySep 2024
NCT05445843JDQ443Phase 2Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationOncologyNov 2024
NCT03827798Ianalumab (VAY736)Phase 2Hidradenitis SuppurativaImmunologyDec 2024
NCT03827798remibrutinib (LOU064)Phase 2Hidradenitis SuppurativaImmunologyDec 2024
NCT03827798Arumakimig (MAS825)Phase 2Hidradenitis SuppurativaImmunologyDec 2024
NCT03827798Iscalimab (CFZ533)Phase 2Hidradenitis SuppurativaImmunologyDec 2024
NCT03827798LYS006Phase 2Hidradenitis SuppurativaImmunologyDec 2024
NCT03944434Ribociclib (LEE011)Phase 2Breast CancerOncologyDec 2024
NCT03874884Lutetium Lu-177 Vipivotide Tetraxetan (AAA617)Phase 1Metastatic Castration Resistant Prostate Cancer (mCRPC)OncologyMay 2025
NCT06338293Inclisiran sodiumPhase 4Coronary Artery DiseaseCardiovascularJun 2025
NCT04762979Alpelisib (BYL719)Phase 2Hormone Receptor Positive Breast CarcinomaOncologyOct 2025
NCT06444113OfatumumabPhase 4Multiple SclerosisNeurologyFeb 2026
NCT04343885Lutetium Lu-177 Vipivotide Tetraxetan (AAA617)Phase 2Metastatic Hormone Naive Prostate CancerOncologyMar 2026
NCT05268289IptacopanPhase 2Lupus NephritisImmunologyMar 2026
NCT03285412Ribociclib (LEE011)Phase 2Breast CancerOncologyApr 2026
NCT05504694OfatumumabPhase 1Neuromyelitis Optica Spectrum DisorderNeurologyApr 2026
NCT05750628INE963Phase 2Uncomplicated Plasmodium Falciparum MalariaInfectious diseaseJun 2026
NCT05750628Cipargamin (KAE609)Phase 2Uncomplicated Plasmodium Falciparum MalariaInfectious diseaseJun 2026
NCT05750628KLU156Phase 2Uncomplicated Plasmodium Falciparum MalariaInfectious diseaseJun 2026
NCT02446444EnzalutamidePhase 3Prostatic NeoplasmsOncologyJun 2026
NCT06372821NIO752Phase 1Alzheimer DiseaseNeurologyJul 2026
NCT03091257DabrafenibPhase 1Multiple MyelomaOncologyJul 2026
NCT03091257TrametinibPhase 1Multiple MyelomaOncologyJul 2026
NCT01087554everolimusPhase 1Advanced CancerOncologyAug 2026
NCT05230537IptacopanPhase 2Age-Related Macular DegenerationOphthalmologyAug 2026
NCT05303285SecukinumabPhase 4Ankylosing Spondylitis (AS)ImmunologyAug 2026
NCT05132075JDQ443Phase 3Non-Small Cell Lung CancerOncologySep 2026
NCT05358249JDQ443Phase 1KRAS G12C Mutant Solid TumorsOncologySep 2026
NCT06379217[177Lu]Lu-PSMA-617Phase 1Metastatic Neuroendocrine Prostate CancerOncologyOct 2026
NCT06379217[177Lu]Lu-PSMA-617Phase 1Metastatic Neuroendocrine Prostate CancerOncologyOct 2026
NCT06379217[177Lu]Lu-DOTA-TATEPhase 1Metastatic Neuroendocrine Prostate CancerOncologyOct 2026
NCT05252585everolimusPhase 4Renal AngiomyolipomaGenitourinaryOct 2026
NCT03090165Ribociclib (LEE011)Phase 1Triple Negative Breast CancerOncologyOct 2026
NCT06894511Lutetium Lu-177 Vipivotide Tetraxetan (AAA617)Phase 2Metastatic Castration Resistant Prostate Cancer (mCRPC)OncologyOct 2026
NCT05360446Inclisiran sodiumPhase 3Coronary Artery DiseaseCardiovascularOct 2026
NCT03975829DabrafenibPhase 4Diffuse AstrocytomaOncologyNov 2026
NCT03975829TrametinibPhase 4Diffuse AstrocytomaOncologyNov 2026
NCT07783503PelabresibPhase 1Healthy ParticipantsOtherNov 2026
NCT04097470MidostaurinPhase 2AML/MDSOncologyNov 2026
NCT06501443Inclisiran sodiumPhase 4HypercholesterolaemiaCardiovascularNov 2026
NCT05660083Alpelisib (BYL719)Phase 2HER2-negative Breast CancerOncologyDec 2026
NCT06852820Lutetium Lu-177 Vipivotide Tetraxetan (AAA617)Phase 2Liver CancerOncologyDec 2026
NCT06964958Lutetium Lu-177 Vipivotide Tetraxetan (AAA617)Phase 2Renal Cell CarcinomaOncologyDec 2026
NCT06555237TrametinibPhase 2CardiomegalyCardiovascularDec 2026
NCT04419402EnzalutamidePhase 2Metastatic Castration-Resistant Prostate CancerOncologyDec 2026
NCT04797000EltrombopagPhase 2Myelodysplastic SyndromesHematologyDec 2026
NCT05081193EnzalutamidePhase 2Prostate CancerOncologyDec 2026
NCT07465653HJB647Phase 1Heart Failure With Reduced Ejection FractionCardiovascularDec 2026
NCT06004661Lutetium Lu-177 Vipivotide Tetraxetan (AAA617)Phase 2Metastatic Castration-Resistant Prostate Cancer (mCRPC)OncologyDec 2026
NCT03114527Ribociclib (LEE011)Phase 2Soft Tissue SarcomaOncologyDec 2026
NCT02712723Ribociclib (LEE011)Phase 2Breast CancerOncologyDec 2026
NCT05143229Alpelisib (BYL719)Phase 1Breast CancerOncologyDec 2026
NCT05340374Lutetium Lu-177 Vipivotide Tetraxetan (AAA617)Phase 1Metastatic Castration-resistant Prostate CancerOncologyDec 2026

The 60 nearest readouts of 577 trials; the rest in the app.

From the company's SEC filings

Cash and short-term investments of $11.6bn on 2025-12-31; operating cash flow positive

Complete response letters from FDA

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

FOLH1 (3) SMN1 (3) DLL3 (3) GRPR (2) SSTR2 (2) KRAS (2) BRAF (2) S1PR1 (2) AR (2) SMN2 (2) CDK4 (1) CDK6 (1)

Companies with the same targets

Revolution Medicines Boehringer Ingelheim Eli Lilly Johnson & Johnson (Janssen) Amgen Jiangsu HengRui Medicine TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Roche Telix Pharmaceuticals (Innovations)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.